Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 86 entries
Sorted by: Best Match Show Resources per page
Prevention of Stroke.

The American journal of geriatric cardiology

Ezekowitz MD.
PMID: 11416473
Am J Geriatr Cardiol. 1998 Oct;7(5):42-46.

Patients with atrial fibrillation are at variable risks for developing a stroke. The risk is significantly increased among the elderly. Other risks factors include hypertension, diabetes, poor ventricular function, and a prior history of TIA or stroke. Among the...

Cite
Ezekowitz MD. Prevention of Stroke. Am J Geriatr Cardiol. 1998;7(5):42-46
Ezekowitz, M. D. (1998). Prevention of Stroke. The American journal of geriatric cardiology, 7(5), 42-46.
Ezekowitz, Michael D.. "Prevention of Stroke." The American journal of geriatric cardiology vol. 7,5 (1998): 42-46.
Ezekowitz MD. Prevention of Stroke. Am J Geriatr Cardiol. 1998 Oct;7(5):42-46. PMID: 11416473.
Copy Download .nbib Format: NLM
New developments in anticoagulation for atrial fibrillation.

Current treatment options in cardiovascular medicine

Usman MH, Notaro LA, Patel H, Ezekowitz MD.
PMID: 18814828
Curr Treat Options Cardiovasc Med. 2008 Sep;10(5):388-97. doi: 10.1007/s11936-008-0030-0.

The incidence of stroke in patients with atrial fibrillation (AF) is five times greater than that in age-matched controls. Warfarin reduces this incidence by two thirds and is the most effective agent for this indication. However, despite its efficacy,...

Cite
Usman MH, Notaro LA, Patel H, et al. New developments in anticoagulation for atrial fibrillation. Curr Treat Options Cardiovasc Med. 2008;10(5):388-97doi: 10.1007/s11936-008-0030-0.
Usman, M. H., Notaro, L. A., Patel, H., & Ezekowitz, M. D. (2008). New developments in anticoagulation for atrial fibrillation. Current treatment options in cardiovascular medicine, 10(5), 388-97. https://doi.org/10.1007/s11936-008-0030-0
Usman, M Haris U, et al. "New developments in anticoagulation for atrial fibrillation." Current treatment options in cardiovascular medicine vol. 10,5 (2008): 388-97. doi: https://doi.org/10.1007/s11936-008-0030-0
Usman MH, Notaro LA, Patel H, Ezekowitz MD. New developments in anticoagulation for atrial fibrillation. Curr Treat Options Cardiovasc Med. 2008 Sep;10(5):388-97. doi: 10.1007/s11936-008-0030-0. PMID: 18814828.
Copy Download .nbib Format: NLM
Cardiac resynchronisation therapy is efficacious in patients with mild heart failure symptoms.

Evidence-based medicine

Al-Majed NS, Ezekowitz JA.
PMID: 21436182
Evid Based Med. 2011 Oct;16(5):138-9. doi: 10.1136/ebm1029. Epub 2011 Mar 24.

No abstract available.

Cite
Al-Majed NS, Ezekowitz JA. Cardiac resynchronisation therapy is efficacious in patients with mild heart failure symptoms. Evid Based Med. 2011;16(5):138-9doi: 10.1136/ebm1029.
Al-Majed, N. S., & Ezekowitz, J. A. (2011). Cardiac resynchronisation therapy is efficacious in patients with mild heart failure symptoms. Evidence-based medicine, 16(5), 138-9. https://doi.org/10.1136/ebm1029
Al-Majed, Nawaf S, and Ezekowitz, Justin A. "Cardiac resynchronisation therapy is efficacious in patients with mild heart failure symptoms." Evidence-based medicine vol. 16,5 (2011): 138-9. doi: https://doi.org/10.1136/ebm1029
Al-Majed NS, Ezekowitz JA. Cardiac resynchronisation therapy is efficacious in patients with mild heart failure symptoms. Evid Based Med. 2011 Oct;16(5):138-9. doi: 10.1136/ebm1029. Epub 2011 Mar 24. PMID: 21436182.
Copy Download .nbib Format: NLM
Exploring the pragmatic-explanatory spectrum across cardiovascular clinical trials.

Contemporary clinical trials

Harrington J, Gouda P, Ezekowitz J, Mentz RJ.
PMID: 34863929
Contemp Clin Trials. 2021 Dec 01;113:106646. doi: 10.1016/j.cct.2021.106646. Epub 2021 Dec 01.

Clinical trials are a cornerstone of modern medicine and form the backbone of evidence that is used to create evidence-based guidelines. Contemporary clinical trials have tended to be quite explanatory, assessing an intervention in ideal conditions with highlyprotocolized interventions,...

Cite
Harrington J, Gouda P, Ezekowitz J, et al. Exploring the pragmatic-explanatory spectrum across cardiovascular clinical trials. Contemp Clin Trials. 2021;113:106646doi: 10.1016/j.cct.2021.106646.
Harrington, J., Gouda, P., Ezekowitz, J., & Mentz, R. J. (2021). Exploring the pragmatic-explanatory spectrum across cardiovascular clinical trials. Contemporary clinical trials, 113106646. https://doi.org/10.1016/j.cct.2021.106646
Harrington, Josephine, et al. "Exploring the pragmatic-explanatory spectrum across cardiovascular clinical trials." Contemporary clinical trials vol. 113 (2021): 106646. doi: https://doi.org/10.1016/j.cct.2021.106646
Harrington J, Gouda P, Ezekowitz J, Mentz RJ. Exploring the pragmatic-explanatory spectrum across cardiovascular clinical trials. Contemp Clin Trials. 2021 Dec 01;113:106646. doi: 10.1016/j.cct.2021.106646. Epub 2021 Dec 01. PMID: 34863929.
Copy Download .nbib Format: NLM
Cardiac and Cardiometabolic Phenotyping of Trastuzumab-Mediated Cardiotoxicity: a Secondary Analysis of the MANTICORE trial.

European heart journal. Cardiovascular pharmacotherapy

Kirkham AA, Pituskin E, Thompson RB, Mackey JR, Koshman SL, Jassal D, Pitz M, Haykowsky MJ, Pagano JJ, Chow K, Tsui AK, Ezekowitz JA, Oudit GY, Paterson DI.
PMID: 33605416
Eur Heart J Cardiovasc Pharmacother. 2021 Feb 19; doi: 10.1093/ehjcvp/pvab016. Epub 2021 Feb 19.

AIMS: An improved understanding of the pathophysiology of trastuzumab-mediated cardiotoxicity is required to improve outcomes of patients with HER2-positive breast cancer. We aimed to characterize the cardiac and cardiometabolic phenotype of trastuzumab-mediated toxicity and potential interactions with cardiac pharmacotherapy.METHODS...

Cite
Kirkham AA, Pituskin E, Thompson RB, et al. Cardiac and Cardiometabolic Phenotyping of Trastuzumab-Mediated Cardiotoxicity: a Secondary Analysis of the MANTICORE trial. Eur Heart J Cardiovasc Pharmacother. 2021;doi: 10.1093/ehjcvp/pvab016.
Kirkham, A. A., Pituskin, E., Thompson, R. B., Mackey, J. R., Koshman, S. L., Jassal, D., Pitz, M., Haykowsky, M. J., Pagano, J. J., Chow, K., Tsui, A. K., Ezekowitz, J. A., Oudit, G. Y., & Paterson, D. I. (2021). Cardiac and Cardiometabolic Phenotyping of Trastuzumab-Mediated Cardiotoxicity: a Secondary Analysis of the MANTICORE trial. European heart journal. Cardiovascular pharmacotherapy, . https://doi.org/10.1093/ehjcvp/pvab016
Kirkham, Amy A, et al. "Cardiac and Cardiometabolic Phenotyping of Trastuzumab-Mediated Cardiotoxicity: a Secondary Analysis of the MANTICORE trial." European heart journal. Cardiovascular pharmacotherapy vol. (2021). doi: https://doi.org/10.1093/ehjcvp/pvab016
Kirkham AA, Pituskin E, Thompson RB, Mackey JR, Koshman SL, Jassal D, Pitz M, Haykowsky MJ, Pagano JJ, Chow K, Tsui AK, Ezekowitz JA, Oudit GY, Paterson DI. Cardiac and Cardiometabolic Phenotyping of Trastuzumab-Mediated Cardiotoxicity: a Secondary Analysis of the MANTICORE trial. Eur Heart J Cardiovasc Pharmacother. 2021 Feb 19; doi: 10.1093/ehjcvp/pvab016. Epub 2021 Feb 19. PMID: 33605416.
Copy Download .nbib Format: NLM
Exploring the pragmatic-explanatory spectrum across cardiovascular clinical trials.

Contemporary clinical trials

Harrington J, Gouda P, Ezekowitz J, Mentz RJ.
PMID: 34863929
Contemp Clin Trials. 2021 Dec 01;113:106646. doi: 10.1016/j.cct.2021.106646. Epub 2021 Dec 01.

Clinical trials are a cornerstone of modern medicine and form the backbone of evidence that is used to create evidence-based guidelines. Contemporary clinical trials have tended to be quite explanatory, assessing an intervention in ideal conditions with highlyprotocolized interventions,...

Cite
Harrington J, Gouda P, Ezekowitz J, et al. Exploring the pragmatic-explanatory spectrum across cardiovascular clinical trials. Contemp Clin Trials. 2021;113:106646doi: 10.1016/j.cct.2021.106646.
Harrington, J., Gouda, P., Ezekowitz, J., & Mentz, R. J. (2021). Exploring the pragmatic-explanatory spectrum across cardiovascular clinical trials. Contemporary clinical trials, 113106646. https://doi.org/10.1016/j.cct.2021.106646
Harrington, Josephine, et al. "Exploring the pragmatic-explanatory spectrum across cardiovascular clinical trials." Contemporary clinical trials vol. 113 (2021): 106646. doi: https://doi.org/10.1016/j.cct.2021.106646
Harrington J, Gouda P, Ezekowitz J, Mentz RJ. Exploring the pragmatic-explanatory spectrum across cardiovascular clinical trials. Contemp Clin Trials. 2021 Dec 01;113:106646. doi: 10.1016/j.cct.2021.106646. Epub 2021 Dec 01. PMID: 34863929.
Copy Download .nbib Format: NLM
Real world Data on the Concurrent Use of P-glycoprotein or Cytochrome 3A4 Drugs and Non-vitamin K Antagonist Oral Anticoagulants in Non-Valvular Atrial Fibrillation.

European heart journal. Quality of care & clinical outcomes

Sandhu RK, Islam S, Dover D, Andrade JG, Ezekowitz J, McAlister FA, Hawkins NM, Kaul P.
PMID: 33480405
Eur Heart J Qual Care Clin Outcomes. 2021 Jan 22; doi: 10.1093/ehjqcco/qcab002. Epub 2021 Jan 22.

AIM: To determine the concurrent use of P-glycoprotein (P-gp) or Cytochrome (CYP) 3A4 drugs and non-vitamin K antagonist oral anticoagulants (NOACs) among non-valvular AF (NVAF) patients in clinical practice.METHODS AND RESULTS: Administrative databases identified all adults (≥ 18 years)...

Cite
Sandhu RK, Islam S, Dover D, et al. Real world Data on the Concurrent Use of P-glycoprotein or Cytochrome 3A4 Drugs and Non-vitamin K Antagonist Oral Anticoagulants in Non-Valvular Atrial Fibrillation. Eur Heart J Qual Care Clin Outcomes. 2021;doi: 10.1093/ehjqcco/qcab002.
Sandhu, R. K., Islam, S., Dover, D., Andrade, J. G., Ezekowitz, J., McAlister, F. A., Hawkins, N. M., & Kaul, P. (2021). Real world Data on the Concurrent Use of P-glycoprotein or Cytochrome 3A4 Drugs and Non-vitamin K Antagonist Oral Anticoagulants in Non-Valvular Atrial Fibrillation. European heart journal. Quality of care & clinical outcomes, . https://doi.org/10.1093/ehjqcco/qcab002
Sandhu, Roopinder K, et al. "Real world Data on the Concurrent Use of P-glycoprotein or Cytochrome 3A4 Drugs and Non-vitamin K Antagonist Oral Anticoagulants in Non-Valvular Atrial Fibrillation." European heart journal. Quality of care & clinical outcomes vol. (2021). doi: https://doi.org/10.1093/ehjqcco/qcab002
Sandhu RK, Islam S, Dover D, Andrade JG, Ezekowitz J, McAlister FA, Hawkins NM, Kaul P. Real world Data on the Concurrent Use of P-glycoprotein or Cytochrome 3A4 Drugs and Non-vitamin K Antagonist Oral Anticoagulants in Non-Valvular Atrial Fibrillation. Eur Heart J Qual Care Clin Outcomes. 2021 Jan 22; doi: 10.1093/ehjqcco/qcab002. Epub 2021 Jan 22. PMID: 33480405.
Copy Download .nbib Format: NLM
Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine.

Diabetes care

Sharma A, Zheng Y, Ezekowitz JA, Westerhout CM, Udell JA, Goodman SG, Armstrong PW, Buse JB, Green JB, Josse RG, Kaufman KD, McGuire DK, Ambrosio G, Chuang LM, Lopes RD, Peterson ED, Holman RR.
PMID: 34716214
Diabetes Care. 2021 Oct 29; doi: 10.2337/dc20-2806. Epub 2021 Oct 29.

OBJECTIVE: Phenotypic heterogeneity among patients with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease (ASCVD) is ill defined. We used cluster analysis machine-learning algorithms to identify phenotypes among trial participants with T2DM and ASCVD.RESEARCH DESIGN AND METHODS: We...

Cite
Sharma A, Zheng Y, Ezekowitz JA, et al. Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine. Diabetes Care. 2021;doi: 10.2337/dc20-2806.
Sharma, A., Zheng, Y., Ezekowitz, J. A., Westerhout, C. M., Udell, J. A., Goodman, S. G., Armstrong, P. W., Buse, J. B., Green, J. B., Josse, R. G., Kaufman, K. D., McGuire, D. K., Ambrosio, G., Chuang, L. M., Lopes, R. D., Peterson, E. D., & Holman, R. R. (2021). Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine. Diabetes care, . https://doi.org/10.2337/dc20-2806
Sharma, Abhinav, et al. "Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine." Diabetes care vol. (2021). doi: https://doi.org/10.2337/dc20-2806
Sharma A, Zheng Y, Ezekowitz JA, Westerhout CM, Udell JA, Goodman SG, Armstrong PW, Buse JB, Green JB, Josse RG, Kaufman KD, McGuire DK, Ambrosio G, Chuang LM, Lopes RD, Peterson ED, Holman RR. Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine. Diabetes Care. 2021 Oct 29; doi: 10.2337/dc20-2806. Epub 2021 Oct 29. PMID: 34716214.
Copy Download .nbib Format: NLM
Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial.

JAMA cardiology

Lam CSP, Giczewska A, Sliwa K, Edelmann F, Refsgaard J, Bocchi E, Ezekowitz JA, Hernandez AF, O'Connor CM, Roessig L, Patel MJ, Pieske B, Anstrom KJ, Armstrong PW.
PMID: 33185650
JAMA Cardiol. 2021 Jun 01;6(6):706-712. doi: 10.1001/jamacardio.2020.6455.

IMPORTANCE: The period following heart failure hospitalization (HFH) is a vulnerable time with high rates of death or recurrent HFH.OBJECTIVE: To evaluate clinical characteristics, outcomes, and treatment response to vericiguat according to prespecified index event subgroups and time from...

Cite
Lam CSP, Giczewska A, Sliwa K, et al. Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial. JAMA Cardiol. 2021;6(6):706-712doi: 10.1001/jamacardio.2020.6455.
Lam, C. S. P., Giczewska, A., Sliwa, K., Edelmann, F., Refsgaard, J., Bocchi, E., Ezekowitz, J. A., Hernandez, A. F., O'Connor, C. M., Roessig, L., Patel, M. J., Pieske, B., Anstrom, K. J., Armstrong, P. W. (2021). Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial. JAMA cardiology, 6(6), 706-712. https://doi.org/10.1001/jamacardio.2020.6455
Lam, Carolyn S P, et al. "Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial." JAMA cardiology vol. 6,6 (2021): 706-712. doi: https://doi.org/10.1001/jamacardio.2020.6455
Lam CSP, Giczewska A, Sliwa K, Edelmann F, Refsgaard J, Bocchi E, Ezekowitz JA, Hernandez AF, O'Connor CM, Roessig L, Patel MJ, Pieske B, Anstrom KJ, Armstrong PW. Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial. JAMA Cardiol. 2021 Jun 01;6(6):706-712. doi: 10.1001/jamacardio.2020.6455. PMID: 33185650; PMCID: PMC7666431.
Copy Download .nbib Format: NLM
Cardiac remodelling predicts outcome in patients with chronic heart failure.

ESC heart failure

Xu L, Pagano J, Chow K, Oudit GY, Haykowsky MJ, Mikami Y, Howarth AG, White JA, Howlett JG, Dyck JRB, Anderson TJ, Ezekowitz JA, Thompson RB, Paterson DI.
PMID: 34569184
ESC Heart Fail. 2021 Dec;8(6):5352-5362. doi: 10.1002/ehf2.13626. Epub 2021 Sep 26.

AIMS: Surveillance imaging is often used to detect remodelling, a change in cardiac geometry, and/or function; however, there are limited data in patients with chronic heart failure (HF). We sought to characterize cardiac remodelling in patients with chronic HF...

Cite
Xu L, Pagano J, Chow K, et al. Cardiac remodelling predicts outcome in patients with chronic heart failure. ESC Heart Fail. 2021;8(6):5352-5362doi: 10.1002/ehf2.13626.
Xu, L., Pagano, J., Chow, K., Oudit, G. Y., Haykowsky, M. J., Mikami, Y., Howarth, A. G., White, J. A., Howlett, J. G., Dyck, J. R. B., Anderson, T. J., Ezekowitz, J. A., Thompson, R. B., & Paterson, D. I. (2021). Cardiac remodelling predicts outcome in patients with chronic heart failure. ESC heart failure, 8(6), 5352-5362. https://doi.org/10.1002/ehf2.13626
Xu, Lingyu, et al. "Cardiac remodelling predicts outcome in patients with chronic heart failure." ESC heart failure vol. 8,6 (2021): 5352-5362. doi: https://doi.org/10.1002/ehf2.13626
Xu L, Pagano J, Chow K, Oudit GY, Haykowsky MJ, Mikami Y, Howarth AG, White JA, Howlett JG, Dyck JRB, Anderson TJ, Ezekowitz JA, Thompson RB, Paterson DI. Cardiac remodelling predicts outcome in patients with chronic heart failure. ESC Heart Fail. 2021 Dec;8(6):5352-5362. doi: 10.1002/ehf2.13626. Epub 2021 Sep 26. PMID: 34569184.
Copy Download .nbib Format: NLM
Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial.

European heart journal. Cardiovascular pharmacotherapy

De Caterina R, Patti G, Westerbergh J, Horowitz J, Ezekowitz JA, Lewis BS, Lopes RD, McMurray JJV, Atar D, Bahit MC, Keltai M, López-Sendón JL, Ruzyllo W, Granger CB, Alexander JH, Wallentin L.
PMID: 33367487
Eur Heart J Cardiovasc Pharmacother. 2020 Dec 28; doi: 10.1093/ehjcvp/pvaa140. Epub 2020 Dec 28.

AIMS: Whether diabetes without insulin therapy is an independent cardiovascular (CV) risk factor in atrial fibrillation (AF) has recently been questioned. We investigated the prognostic relevance of diabetes with or without insulin treatment in patients in the ARISTOTLE trial.METHODS...

Cite
De Caterina R, Patti G, Westerbergh J, et al. Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. Eur Heart J Cardiovasc Pharmacother. 2020;doi: 10.1093/ehjcvp/pvaa140.
De Caterina, R., Patti, G., Westerbergh, J., Horowitz, J., Ezekowitz, J. A., Lewis, B. S., Lopes, R. D., McMurray, J. J. V., Atar, D., Bahit, M. C., Keltai, M., López-Sendón, J. L., Ruzyllo, W., Granger, C. B., Alexander, J. H., & Wallentin, L. (2020). Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. European heart journal. Cardiovascular pharmacotherapy, . https://doi.org/10.1093/ehjcvp/pvaa140
De Caterina, Raffaele, et al. "Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial." European heart journal. Cardiovascular pharmacotherapy vol. (2020). doi: https://doi.org/10.1093/ehjcvp/pvaa140
De Caterina R, Patti G, Westerbergh J, Horowitz J, Ezekowitz JA, Lewis BS, Lopes RD, McMurray JJV, Atar D, Bahit MC, Keltai M, López-Sendón JL, Ruzyllo W, Granger CB, Alexander JH, Wallentin L. Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. Eur Heart J Cardiovasc Pharmacother. 2020 Dec 28; doi: 10.1093/ehjcvp/pvaa140. Epub 2020 Dec 28. PMID: 33367487.
Copy Download .nbib Format: NLM
Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease.

Cardiovascular research

Benz AP, Healey JS, Chin A, Commerford P, Marsden T, Karthikeyan G, McIntyre WF, Wong JA, Damasceno A, Hohnloser SH, Oldgren J, Wallentin L, Ezekowitz MD, Eikelboom JW, Yusuf S, Connolly SJ.
PMID: 33386845
Cardiovasc Res. 2022 Jan 07;118(1):295-304. doi: 10.1093/cvr/cvaa344.

AIMS: Patients with atrial fibrillation (AF) and rheumatic heart disease (RHD), especially mitral stenosis, are assumed to be at high risk of stroke, irrespective of other factors. We aimed to re-evaluate stroke risk factors in a contemporary cohort of...

Cite
Benz AP, Healey JS, Chin A, et al. Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease. Cardiovasc Res. 2022;118(1):295-304doi: 10.1093/cvr/cvaa344.
Benz, A. P., Healey, J. S., Chin, A., Commerford, P., Marsden, T., Karthikeyan, G., McIntyre, W. F., Wong, J. A., Damasceno, A., Hohnloser, S. H., Oldgren, J., Wallentin, L., Ezekowitz, M. D., Eikelboom, J. W., Yusuf, S., & Connolly, S. J. (2022). Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease. Cardiovascular research, 118(1), 295-304. https://doi.org/10.1093/cvr/cvaa344
Benz, Alexander P, et al. "Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease." Cardiovascular research vol. 118,1 (2022): 295-304. doi: https://doi.org/10.1093/cvr/cvaa344
Benz AP, Healey JS, Chin A, Commerford P, Marsden T, Karthikeyan G, McIntyre WF, Wong JA, Damasceno A, Hohnloser SH, Oldgren J, Wallentin L, Ezekowitz MD, Eikelboom JW, Yusuf S, Connolly SJ. Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease. Cardiovasc Res. 2022 Jan 07;118(1):295-304. doi: 10.1093/cvr/cvaa344. PMID: 33386845.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 86 entries